1. Home
  2. Medical Research
  3. New York, NY
  4. Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation is ranked #32 of 39 medical research organizations in New York, NY, with an America's Best Score of 64 out of 100, based on its 2025 Form 990.

  • New York, NY
  • Tax-exempt since 2001
  • EIN: 13-4137654
hnf-cure.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
64OF 100 #32 of 39 in New York ranked medical research organizations How this score is calculated

Organization summary

Hereditary Neuropathy Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H129). Contributions are tax-deductible.

1641 3Rd Ave, New York, NY 10128-3623

Among the 61 scored medical research organizations in New York, Hereditary Neuropathy Foundation holds 13.5 months of operating reserves (peer median 13.5 months), runs a typical yearly deficit of 14.6% (peers: surplus of 3.4%), and has grown spending 5.6% a year (peers: grown spending 7.0% a year).

In fiscal year 2025 it reported $545,418 in revenue and $894,903 in expenses, with contributions making up 106.8% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Hnf, inc., a non-profit dedicated to supporting projects through the therapeutic research in accelerated discovery (triad)program, a collaborative effort with academia, government and industry, to develop treatments for cmt. Currently triad involves many groups that span the drug discovery, drug development, and diagnostics continuum. Education and support of the cmt community to improve quality of life is also a key component of hnf's mission.

Main program · fiscal year 2025

  • Research programs are as follows: Therapeutic research in accelerated discovery (triad) continues to serve as hnf's primary translational research accelerator, supporting the development of essential research tools (including ipscs and animal models), therapeutic candidates, drug screening initiatives, gene therapy programs, and digital health technology innovations. The program maintains strong p… Read more

    Research programs are as follows: Therapeutic research in accelerated discovery (triad) continues to serve as hnf's primary translational research accelerator, supporting the development of essential research tools (including ipscs and animal models), therapeutic candidates, drug screening initiatives, gene therapy programs, and digital health technology innovations. The program maintains strong partnerships with academic institutions, regulatory agencies, and industry collaborators and advances key scientific initiatives in biomarker development, clinical endpoint refinement, and therapy translation. Triad also leads the annual cmt clinical trial readiness summit, which brings together global experts to align on regulatory expectations, optimize trial design, and accelerate therapy development. The global registry for inherited neuropathies (grin) continues to grow as an international cmt patient registry, capturing natural history data and providing comprehensive patient-reported, clinical, digital, and genetic datasets. Grin plays a critical role in clinical trial readiness, supporting feasibility assessments, endpoint development, and patient recruitment for therapeutic development programs. Grin insights and data infrastructure inform key sessions and working groups at the cmt clinical trial readiness summit, helping researchers and industry partners address unmet needs and strengthen future trial strategies. The cmt biobank continues to expand its patient sample collection, including blood, saliva, tissue, skin fibroblasts, ipscs, and other biospecimens donated by individuals with cmt. These samples are processed and stored under strict quality-controlled protocols and remain securely linked to grin clinical, digital, and genetic data. This integrated resource supports pre-competitive biomarker discovery, molecular research, and digital biomarker validation, enabling researchers and industry partners to accelerate therapeutic development. Findings and collaborative opportunities from the biobank are regularly highlighted at the cmt clinical trial readiness summit, where cross-sector partners align on biomarker priorities and strategies to advance future treatments.

    $805,802 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 90¢ went to programs, 6¢ to management and 4¢ to fundraising.

  • Programs $805,802
  • Management $55,157
  • Fundraising $33,944

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score64 / 100
Rank in New York#32 of 39
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves13.5 mo; 8.7 mo in cash9.4 / 25
Financial balance (median margin)−14.6%4.2 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+5.6% / yr10.3 / 15
Track record25 years10 / 10
Debt load0.6% of assets10 / 10
Total63.9 → 64
Spending on programs
Not scored; America's Best needs 65%+
90%Meets

Compared with New York peers

MeasureThis organizationPeer median
Operating reserves13.5 mo13.5 mo
Typical margin−14.6%+3.4%
Spending growth+5.6% / yr+7.0% / yr
Debt load0.6%13.5%

Peers: the 61 New York medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$545,418Fiscal year 20252022: $1,259,87920222023: $543,62520232024: $655,29620242025: $545,4182025
Expenses$894,903Fiscal year 20252022: $759,37420222023: $671,49120232024: $730,00320242025: $894,9032025
Total assets$1,016,066Fiscal year 20252022: $1,627,05320222023: $1,515,44820232024: $1,503,54120242025: $1,016,0662025
Total liabilities$6,182Fiscal year 20252022: $5,58920222023: $12,28220232024: $62,34320242025: $6,1822025
Fiscal year ending June 2025
Revenue$545,418
Expenses$894,903
Net income−$349,485
Net assets$1,009,884

Notable sources of revenue

Percent of total revenue
Contributions$582,345
Program services$0
Investment income$5,908
Other (net)−$42,835

Assets / debt

Total assets$1,016,066
Total liabilities$6,182
Net assets$1,009,884

Compensation

Not in our extract for this year.

Fiscal year ending June 2024
Revenue$655,296
Expenses$730,003
Net income−$74,707
Net assets$1,441,198

Notable sources of revenue

Percent of total revenue
Contributions$713,969
Program services$0
Investment income$5,540
Other (net)−$64,213

Assets / debt

Total assets$1,503,541
Total liabilities$62,343
Net assets$1,441,198

Compensation

Not in our extract for this year.

Fiscal year ending June 2023
Revenue$543,625
Expenses$671,491
Net income−$127,866
Net assets$1,503,166

Notable sources of revenue

Percent of total revenue
Contributions$559,719
Program services$0
Investment income$5,104
Other (net)−$21,198

Assets / debt

Total assets$1,515,448
Total liabilities$12,282
Net assets$1,503,166

Compensation

Officers and key employees$66,346
Share of expenses9.9%
Fiscal year ending June 2022
Revenue$1,259,879
Expenses$759,374
Net income$500,505
Net assets$1,621,464

Notable sources of revenue

Percent of total revenue
Contributions$1,159,086
Program services$0
Investment income$1,424
Other (net)$99,369

Assets / debt

Total assets$1,627,053
Total liabilities$5,589
Net assets$1,621,464

Compensation

Officers and key employees$60,000
Share of expenses7.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?